GeNeuro is a product development company, bringing innovative products from cutting edge science towards clinical development through optimal processes.

GeNeuro develops a pioneering approach for the therapy of diseases associated with human endogenous retrovirus expression, with primary focus on Nervous System diseases.

GeNeuro drives its therapeutic product pipeline development towards neurological disorders such as Multiple Sclerosis, Schizophrenia and other diseases of the nervous system with high unmet medical needs. Multiple Sclerosis is our most advanced indication. GeNeuro’s goal is to move its lead compound, a therapeutic monoclonal antibody for Multiple Sclerosis treatment, into clinical development very soon.

GeNeuro’s goal is to reach therapeutic advantage over existing drugs which mainly delay neurological damages and disability caused by Multiple Sclerosis. GeNeuro’s therapeutic objective is to act upstream of the pro-inflammatory cascade, thus increasing efficacy and safety.

GeNeuro is a pioneer in its approach to human endogenous retrovirus associated disorders. The company’s goal is to optimize the management of the disease, including the treatment, the diagnostic tools and the patient’s follow-up. 

GeNeuro is aiming at excellence, both in internal activities and in collaboration with our partners. The company has a well established network of industrial partners, academic alliances, and is constantly seeking to in-license additional assets complementary to its innovative approach.